Related Experiment Video

Updated: Oct 4, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K

Oligometastatic prostate cancer: is it worth targeting the tip of the iceberg?

Stéphane Supiot1,2, Caroline Rousseau2,3

  • 1Institut de Cancérologie de l'Ouest, Department of Radiation Oncology, Bld Monod, Saint-Herblain, France.

Translational Cancer Research
|February 4, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.4K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.4K

Related Experiment Videos

Last Updated: Oct 4, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.4K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K

Articles linked to this work by shared authors, journal, and citation graph.

General technical considerations on reirradiation and focus on brain and head and neck tumours, suggestions from the Recommendations Commission of the Société française de radiothérapie oncologique.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026

High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial.

The Lancet. Oncology·2026

Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis.

European urology·2026

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026

Study Protocol of OLIGOPELVIS 2-GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer.

European urology oncology·2026

OLIGOPELVIS 2-GETUG P12- elective nodal radiotherapy for oligorecurrent pelvic/para-aortic nodes in prostate cancer: early toxicity of a randomized phase 3 trial.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026

Machine learning-based prediction of survival in breast cancer patients with lung metastasis: a SEER-based study.

Translational cancer research·2026

Mitochondria related gene signature serves as prognosis prediction and risk stratification of cholangiocarcinoma.

Translational cancer research·2026

Potential benefits of local radiotherapy in addition to adjuvant chemotherapy in female patients with triple-negative breast cancer in the absence of distant metastases: a SEER database analysis.

Translational cancer research·2026

CST2 promotes melanoma malignant phenotypes through the IL-6-STAT3-NF-κB signaling axis.

Translational cancer research·2026

Multiple prognostic prediction models for subglottic laryngeal cancer based on machine learning.

Translational cancer research·2026

Inflammation-coagulation biomarkers predict catheter-related thrombosis following peripherally inserted central catheter placement in patients with hematologic malignancies: a retrospective cohort study.

Translational cancer research·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us